Loading clinical trials...
Loading clinical trials...
A 12-week, Phase 2 Open-label, Sequential Dose Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 Treatment in Participants With Congenital Adrenal Hyperplasia (TouCAHn)
Conditions
Interventions
atumelnant (CRN04894)
Locations
27
United States
Crinetics Study Site
Pasadena, California, United States
Crinetics Study Site
Ann Arbor, Michigan, United States
Crinetics Study Site
Minneapolis, Minnesota, United States
Crinetics Study Site
St Louis, Missouri, United States
Crinetics Study Site
Morehead City, North Carolina, United States
Crinetics Study Site
Cleveland, Ohio, United States
Start Date
July 3, 2023
Primary Completion Date
August 22, 2025
Completion Date
August 22, 2025
Last Updated
September 23, 2025
NCT06573723
NCT06712823
NCT03760835
NCT04463316
NCT07536269
NCT06449456
Lead Sponsor
Crinetics Pharmaceuticals Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions